Table 1.
Patient characteristics in the groups with subsequent histopathology, clinical/radiological follow-up, and first-line and second-line treatment
| Variables | Histopathology | Clinical/MRI Follow-up | P-value | First-line Treatment | Second-line Treatment | P-value |
|---|---|---|---|---|---|---|
| N | 104 | 64 | – | 108 | 60 | – |
| Age, y, median (range) | 60 (29–80) | 59 (21–80) | 0.654 | 60 (24–80) | 59 (21–78) | 0.988 |
| Sex, n.(%) | ||||||
| Male | 69 (66) | 39 (61) | 0.479 | 69 (64) | 39 (65) | 0.886 |
| Female | 35 (34) | 25 (39) | 39 (36) | 21 (35) | ||
| Tumor location, n (%) | ||||||
| * Peripheral | 103 (99) | 55 (86) | 0.001 | 103 (95) | 55 (92) | 0.332 |
| ** Central | 1 (1) | 9 (14) | 5 (5) | 5 (8) | ||
| Previous tumor resection, n (%) | ||||||
| Biopsy/partial resection | 14 (13) | 19 (30) | 0.010 | 18 (17) | 15 (25) | 0.194 |
| Subtotal/total resection | 90 (87) | 45 (70) | 90 (83) | 45 (75) | ||
| Prognostic histologic factors, n (%) | ||||||
| MGMT methylation | 52 (50) | 28 (44) | 0.766 | 57 (53) | 23 (38) | 0.229 |
| IDH1 mutation | 9 (9) | 9 (14) | 0.240 | 11 (10) | 7 (12) | 0.700 |
| Corticosteroid intake, n (%) | ||||||
| Dosage ≤10 mg | 76 (73) | 37 (58) | 0.041 | 76 (70) | 37 (62) | 0.251 |
| Dosage >10 mg | 28 (27) | 27 (42) | 32 (30) | 23 (38) | ||
| 18F-FET parameters, median (range) | ||||||
| TBRmax | 3.3 (1.4–5.6) | 2.7 (0.6–6.2) | 0.001 | 3.0 (0.6–6.2) | 3.1 (1.5–5.6) | 0.226 |
| TBRmean | 2.0 (1.2–2.7) | 1.9 (0.6–2.5) | <0.0001 | 2.0 (0.6–2.7) | 2.0 (1.5–2.7) | 0.326 |
| BTV (cm3) | 10.9 (0.0–181) | 16 (0.0–147) | 0.765 | 9.5 (0.0–107) | 19.6 (0.0–181) | 0.005 |
| Performance status, n (%) | ||||||
| 0–1 | 100 (96) | 53 (83) | 0.003 | 101 (94) | 52 (87) | 0.137 |
| 2–4 | 4 (4) | 11 (17) | 7 (7) | 8 (13) | ||
| Subsequent tumor management, n (%) | ||||||
| Biopsy/re-resection | – | – | <0.0001 | 76 (73) | 25 (42) | <0.0001 |
| Follow-up MRI | – | – | 29 (27) | 35 (58) | ||
| Second-line chemotherapy | 66 (64) | 25 (39) | – | – |
* Peripheral locations: frontal, parietal, temporal, and occipital.
** Central locations: butterfly configuration, basal ganglia, thalamus, and brainstem.